Tirofiban

Administration

  • Type: Antiplatelet
  • Dosage Forms: INJ
  • Routes of Administration: IV
  • Common Trade Names: Aggrastat

Adult Dosing

Acute coronary syndrome, Non ST-elevation

  • 25 mcg/kg IV x1, then 0.15 mcg/kg/min IV for up to 18h

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

  • Benefits outweigh risks during pregnancy
  • Risk of maternal hemorrhage during delivery
  • Risk of fetal bleeding

Lactation risk

  • Caution advised while breastfeeding

Renal Dosing

  • Adult:
    • CrCl <60: Decrease maintenance infusion rate 50%
    • HD: Not defined
  • Pediatric: Unavailable

Hepatic Dosing

  • Adult: Not defined
  • Pediatric: Unavailable

Contraindications

  • Allergy to class/drug
  • Thrombocytopenia with prior use
  • Active bleeding
  • Coagulation disorder w/in 30 days
  • Major trauma or surgery w/in 30 days

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: 2 hour
  • Metabolism: Minimal
  • Excretion: Urine 65%, feces 25% (primarily unchanged)

Mechanism of Action

  • Reversibly binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation

Comments

See Also

References

Authors:

Jonathan Warren